Moomoo AI 已提取核心訊息
On February 9, 2024, Invivyd, Inc., a biopharmaceutical company based in Delaware, filed a Form S-3 registration statement with the U.S. Securities and Exchange Commission (SEC). The registration pertains to the potential sale of up to 37,745,998 shares of common stock by selling stockholders. This includes 30,921,286 issued and outstanding shares and 6,824,712 shares issuable upon the exercise of an outstanding common stock purchase warrant. Invivyd will not sell any shares nor receive proceeds from the stockholders' sales. However, the company may receive proceeds from the exercise of the warrant, which could total approximately $23.75 million if exercised for cash. These proceeds would be used for working capital and general corporate purposes. The selling stockholders may sell the shares at market prices or negotiated transactions...Show More
On February 9, 2024, Invivyd, Inc., a biopharmaceutical company based in Delaware, filed a Form S-3 registration statement with the U.S. Securities and Exchange Commission (SEC). The registration pertains to the potential sale of up to 37,745,998 shares of common stock by selling stockholders. This includes 30,921,286 issued and outstanding shares and 6,824,712 shares issuable upon the exercise of an outstanding common stock purchase warrant. Invivyd will not sell any shares nor receive proceeds from the stockholders' sales. However, the company may receive proceeds from the exercise of the warrant, which could total approximately $23.75 million if exercised for cash. These proceeds would be used for working capital and general corporate purposes. The selling stockholders may sell the shares at market prices or negotiated transactions, and the sales may be made on the Nasdaq Global Market, where Invivyd's stock trades under the ticker symbol 'IVVD'. The last reported sale price of Invivyd's common stock was $5.04 per share as of February 8, 2024. Invivyd is identified as an 'emerging growth company' and is subject to reduced public company reporting requirements.
2024年2月9日，總部位於特拉華州的生物製藥公司Invivyd, Inc. 向美國證券交易委員會 (SEC) 提交了S-3表格註冊聲明。該註冊涉及出售股東可能出售多達37,745,998股普通股。這包括30,921,286股已發行和流通股票，以及行使未償還普通股購買權證後可發行的6,824,712股股票。Invivyd不會出售任何股票，也不會從股東的銷售中獲得收益。但是，該公司可能會從行使認股權證中獲得收益，如果以現金形式行使，總額可能約爲2375萬美元。這些收益將用於營運資金和一般公司用途。賣出的股東可以按市場價格或協議交易出售股票，並且可以在納斯達克全球市場上進行銷售，Invivyd的股票交易代碼爲'IVVD'。截至2024年2月8日，Invivyd上次公佈的普通股銷售價格爲每股5.04美元。Invivyd 被認定爲 “新興成長型公司”，上市公司報告要求有所降低。
2024年2月9日，總部位於特拉華州的生物製藥公司Invivyd, Inc. 向美國證券交易委員會 (SEC) 提交了S-3表格註冊聲明。該註冊涉及出售股東可能出售多達37,745,998股普通股。這包括30,921,286股已發行和流通股票，以及行使未償還普通股購買權證後可發行的6,824,712股股票。Invivyd不會出售任何股票，也不會從股東的銷售中獲得收益。但是，該公司可能會從行使認股權證中獲得收益，如果以現金形式行使，總額可能約爲2375萬美元。這些收益將用於營運資金和一般公司用途。賣出的股東可以按市場價格或協議交易出售股票，並且可以在納斯達克全球市場上進行銷售，Invivyd的股票交易代碼爲'IVVD'。截至2024年2月8日，Invivyd上次公佈的普通股銷售價格爲每股5.04美元。Invivyd 被認定爲 “新興成長型公司”，上市公司報告要求有所降低。
有用
沒用